Latest News

SourceBio International shares defy the gloom to move to a premium on their AIM debut


Lab services specialist SourceBio International plc (LON:SBI) defied the early gloom to get off to a premium start on its first day of trading on AIM.

At 9 am the stock was up 11p at 173p, providing those who backed the float with a modest early profit on their investment.

For the business, the £35mln raised will be used to scale up COVID-19 testing capacity as well as paying off shareholder and bank loans.

The positive debut has added around £8mln to SourceBio’s initial £120mln market capitalisation.

Chairman Jay LeCoque said: “We are delighted by the strong support we’ve received from new institutional investors and our existing shareholders.

“Our IPO on AIM allows us to significantly increase our COVID-19 testing capacity, accelerate earnings growth in our core business and execute on potential M&A opportunities.

“It’s an exciting time for our business and we look forward to executing on our ambitious growth plans and delivering value to our shareholders.”

FTSE 100 looks set to flatline after previous big falls as decline in Asia slows and US stock future

Previous article

Christie Group hammered as first-half revenues more than halve

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Latest News